Effect of exercise training on chromogranin A and relationship to N-ANP and inflammatory cytokines in patients with chronic heart failure

International Journal of Cardiology

Volumn 127, Issue 1, 2008, Pages 117-120

  Larsen, Alf Inge ^a,b   Helle, Karen B ^b   Christensen, Monika ^c   Kvaløy, Jan T ^a,d   Aarsland, Torbjørn ^e   Dickstein, Kenneth ^a,b  

^a STAVANGER UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF STAVANGER   (Norway)

^e Stavanger Research   (Norway)

Author keywords

Chromogranin A; Chronic heart failure; IL 8; N ANP; NYHA class II and III; Physical exercise; TNF . IL 6

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CHROMOGRANIN A; CYTOKINE; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; N TERMINAL PRO ATRIAL NATRIURETIC PEPTIDE; NATRIURETIC FACTOR; NITRATE; TUMOR NECROSIS FACTOR ALPHA; WARFARIN;

ADRENERGIC SYSTEM; AGED; ANIMAL MODEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; EXERCISE; HEART FAILURE; HEART MUSCLE; HUMAN; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RATING SCALE; SURVIVAL;

AGED; ATRIAL NATRIURETIC FACTOR; CHROMOGRANIN A; CHRONIC DISEASE; CYTOKINES; EXERCISE THERAPY; HEART FAILURE; HUMANS; MALE; PROGNOSIS;

EID: 43949115889     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2007.04.012     Document Type: Article

References (21)

1. Packer M. The neurohumoral hypothesis: a theory to explain the mechanism of the progression in heart failure. J Am Coll Cardiol 20 (1992) 248-254
2. Cohn J.N., Levine T.B., Olivari M.T., et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 311 (1984) 819-823
3. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 316 (1991) 1429-1435
4. Packer M., Coats A.J., Fowler M.B., et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344 (2001) 1651-1658
5. Goetze J.P., Rehfeld J.F., Videbaek R., Friis-Hansen L., and Kastrup J. B-type natriuretic peptide and its precursor in cardiac venous blood from failing hearts. Eur J Heart Fail 7 (2005) 69-74
6. Helle K.B. The granin family of uniquely acidic proteins of the diffuse neuroendocrine system: comparative and functional aspects. Biol Rev (Cambridge) 79 (2004)
7. Steiner H.J., Weiler R., Ludescher C., Schmid K.W., and Winkler H. Chromogranins A and B are co-localized with atrial natriuretic peptides in secretory granules of rat heart. J Histochem Cytochem 38 (1990) 845-850
8. Helle K.B., and Angeletti R.H. Chromogranin A: a multipurpose prohormone?. Acta Physiol Scand 152 (1994) 165-175
9. Brekke J.F., Osol G.J., and Helle K.B. N-terminal chromogranin-derived peptides as dilators of bovine coronary resistance arteries. Regul Pept 105 (2002) 93-100
10. Corti A., Mannarino C., Mazza R., Angelone T., Longhi R., and Tota B. Chromogranin A N-terminal fragments, vasostatins-1 and the synthetic CGA7-57 act as cardiostatins on the isolated working frog heart. Gen Comp Endocrinol 136 (2004) 217-224
11. Blois A., Holmsen H., Martino G., Corti A., Metz-Boutigue M.H., and Helle K.B. Interactions of chromogranin A-derived vasostatins and monolayers of phosphatidylserine, phosphatidylcholine and phosphatidylethanolamine. Regul Pept 134 (2006) 30-37
12. Ferrero E., Scabini S., Magni E., et al. Chromogranin A protects vessels against tumor necrosis factor α-induced vascular leakage. FASEB J 18 (2004) 554-556
13. Ceconi C., Ferrari R., Bachetti T., et al. Chromogranin A in heart failure. A novel neurohumoral factor and a predictor for mortality. Eur Heart J 23 (2002) 967-974
14. Omland T., Dickstein K., and Syversen U. Association between plasma chromogranin A concentration and long term mortality after myocardial infarction. Am J Med 114 (2003) 25-30
15. Larsen A.I., Aukrust P., Aarsland T., et al. Effect of aerobic exercise training on plasma levels of tumor necrosis factor alpha in patients with heart failure. Am J Cardiol 88 (2001) 805-808
16. Degorce F., Goumon Y., Jaquemart L., et al. A new human chromogranin A (CgA) immunoradiometric assay involving monoclonal antibodies raised against the unprocessed central domain (145-245). Br J Cancer 79 (1999) 65-71
17. O'Connor D.T., Pandlan M.R., Carlton E., Cervenka J.H., and Hslao R.J. Rapid radioimmunoassay of circulating chromogranin A. In vitro stability, exploration of the neuroendocrine characterof neoplasia and assessment of the effect of organ failure. Clin Chem 35 (1989) 1631-1637
18. Sullivan P.A., Grosch C., Lawless D., and O'Connor D.T. Short-term strenuous exercise training: effects on blood pressure and hormonal levels in mild hypertension. Ir J Med Sci 161 (1992) 666-669
19. Rogers P.J., Tyce G.M., Weinshilboum R.M., O'Connor D.T., Bailey K.R., and Bove A.A. Catecholamine metabolic pathways and exercise training. Plasma and urine catecholamines, metabolic enzymes, and chromogranin-A. Circulation 84 (1991) 2346-2356
20. Ferrero E., Scabini S., Magni E., et al. Chromogranin A protects vessels against tumor necrosis factor α-induced vascular leakage. FASEB J 18 (2004) 554-556
21. Lugardon K., Raffner R., Goumon Y., et al. Antibacterial and antifungal activities of vasostatin-1, the N-terminal fragment of chromogranin A. J Biol Chem 275 (2000) 10745-10753